Commented Articles

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide and a significant contributor to liver cirrhosis, transplantation, and hepatocellular carcinoma.

Non-alcoholic fatty liver disease (NAFLD) is currently the fastest-growing indicator for liver transplantation worldwide. Its status as a growing health concern further parallels the global rise of obesity.

Data from the Global Burden of Disease study indicates that non-alcoholic fatty liver disease (NAFLD) is the most rapidly increasing global contributor to chronic liver disease (CLD)-associated complications, which include the onset of cirrhosis and hepatocellular carcinoma.

It is known that traumatic muscle injury damages mitochondria, which may cause them to leak their contents into the cytoplasm and subsequently trigger calcium accumulation, cell death, endoplasmic reticulum stress, and the release of reactive oxygen species (ROS).

Walking speed (WS) is clinically recognized as a crucial vital sign. Associations between daily walking speed (DWS) and health outcomes have been underscored by a number of studies, which have further recognized it as an accurate predictor of dependency and mortality in elderly individuals. Despite this knowledge, very few studies have examined the link between DWS and frailty.

The association between metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD) has been well-characterised by recent literature. As such, patients with NAFLD are disproportionately affected by a range of comorbidities, which include obesity, dyslipidemia, type 2 diabetes mellitus (T2DM), and hypertension.

A non-invasive combined model termed FibroScan-aspartate aminotransferase (FAST) was recently proposed for the diagnosis of fibrotic non-alcoholic steatohepatitis (NASH). Conceptualised for patients with elevated non-alcoholic fatty liver disease (NAFLD) activity scores (≥4) and significant fibrosis

Cirrhosis is the end stage of a number of chronic liver diseases, including non-alcoholic steatohepatitis (NASH). Characterised by the scarring of liver tissue, cirrhosis leads to significant hepatic tissue distortion, which may subsequently cause portal hypertension, hepatic synthetic dysfunction, and hepatocellular carcinoma.

Liver cancer has recently been defined as the third leading cause of cancer globally. Although its main aetiologies are hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol, and non-alcoholic steatohepatitis (NASH), the past decade has seen notable shifts in liver disease burden.

The prevalence of non-alcoholic fatty liver disease (NAFLD) is growing in parallel with that of metabolic diseases. NAFLD and metabolic syndrome, which exacerbates the risk of developing type 2 diabetes, have been shown to be heavily interlinked. Despite recent findings regarding NAFLD’s metabolic basis, its molecular basis remains unclear.

No pharmacologic therapies have yet been approved for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), its progressive form. Instead, NAFLD is currently managed by lifestyle interventions, including dietary modifications and physical exercise. Despite this, evidence regarding the effect of exercise on NAFLD-associated histological endpoints is lacking.